Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Polivy Polatuzumab Vedotin Diffuse large B-cell lymphoma (DLBCL) Reimburse with clinical criteria and/or conditions Complete
Polivy polatuzumab vedotin Large B-cell lymphoma Do not reimburse Complete
Polivy Resubmission polatuzumab vedotin large B-cell lymphoma (LBCL) Pending
Pomalyst Pomalidomide Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete
Pomalyst Pomalidomide Multiple Myeloma Reimburse with clinical criteria and/or conditions Complete
Poteligeo mogamulizumab mycosis fungoides (MF), Sézary syndrome (SS) Reimburse with clinical criteria and/or conditions Complete
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism Cancelled
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete
Pradaxa Dabigatran etexilate Thromboembolism (venous), prevention Do not list Complete
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete